WHAT’S OUR STORY?

We are on a mission to impact patients’ lives.

We have potentially groundbreaking clinical-stage therapies in development that, if approved, offer an innovative approach to essential areas of dermatology.

OUR STORY STARTED HERE

Learn more about the product furthest along in our development pipeline
clascoterone cream 1% for acne

Read more

LATEST NEWS

November 13, 2019
chevron right icon

Cassiopea Announces First Patient to be Enrolled in Phase II Trial for the Treatment of Androgenetic Alopecia in Females with Clascoterone Solution

November 8, 2019
chevron right icon

Cassiopea Announces FDA Acceptance of its New Drug Application for Clascoterone Cream 1%, the First New Mechanism of Action for Acne in Nearly 40 Years

August 20, 2019
chevron right icon

Cassiopea Announces FDA Submission of New Drug Application for Clascoterone Cream 1%, the First New Mechanism of Action for Acne in Nearly 40 Years

Breezula is under investigation in the United States for the treatment of androgenetic alopecia, and the safety and efficacy have not been established by the United States Food and Drug Administration (FDA). The proposed brand name for clascoterone solution 7.5% is not FDA-approved.

Winlevi is under investigation in the United States for the treatment of acne, and the safety and efficacy have not been established by the United States Food and Drug Administration (FDA). The proposed brand name for clascoterone cream 1% is not FDA-approved.